share_log

Guardant Health Announced Preliminary FY2024 Sales Of Approximately $737M, An Increase Of 31% Compared To Consensus Of $723.9M

Guardant Health Announced Preliminary FY2024 Sales Of Approximately $737M, An Increase Of 31% Compared To Consensus Of $723.9M

Guardant Health宣佈2024財年初步銷售額約爲73700萬美元,比共識的7.239億美元增長31%
Benzinga ·  01/13 12:09

Full year 2024 preliminary unaudited financial results

2024年度初步未經審計的財務業績

  • Total revenue of approximately $737 million, an increase of 31%
  • Reported approximately 206,700 oncology clinical tests (excluding Shield) and approximately 40,500 biopharma tests, an increase of 20% and 35%, respectively
  • 總營業收入約爲73700萬,增長31%
  • 報告了約206,700個腫瘤臨牀測試(不包括Shield)和約40,500個生物製藥測試,分別增長20%和35%

Preliminary unaudited free cash flow was approximately negative $84 million for the fourth quarter of 2024, and approximately negative $275 million for the full year 2024. Cash, cash equivalents, restricted cash and marketable debt securities were $944 million as of December 31, 2024.

2024年第四季度初步未經審計的自由現金流約爲負8400萬,2024年度整體約爲負27500萬。截至2024年12月31日,現金、現金等價物、受限現金和可交易的債務證券爲94400萬。

"2024 was an outstanding year for Guardant. We delivered key milestones across the portfolio and completed the upgrade of Guardant360 LDT onto our Smart Liquid Biopsy platform. We finished the year strong with preliminary full year revenue growth of 31%, driven by strong clinical and biopharma revenue and increasing Guardant360 ASPs. Looking ahead, we believe we are well positioned to continue to drive growth in our oncology business," said Helmy Eltoukhy, co-founder and co-CEO.

"2024年是Guardant的傑出一年。我們在各個領域交付了關鍵里程碑,並完成了Guardant360 LDt向我們的智能液體活檢平台的升級。我們以31%的初步年度營業收入增長強勁結束了這一年,這一增長得益於強勁的臨牀和生物製藥營收以及不斷上漲的Guardant360 ASPs。展望未來,我們相信我們在推動腫瘤業務增長方面具備良好的定位," 聯合創始人兼首席執行官Helmy Eltoukhy表示。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論

    聲明

    本頁的譯文內容由軟件翻譯。富途將竭力但卻不能保證翻譯內容之準確和可靠,亦不會承擔因任何不準確或遺漏而引起的任何損失或損害。